海尔生物
(688139)
| 流通市值：104.03亿 | | | 总市值：104.03亿 |
| 流通股本：3.18亿 | | | 总股本：3.18亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,283,832,911.43 | 1,782,020,224.83 | 1,223,284,970.75 | 686,909,061.52 |
| 营业收入 | 2,283,832,911.43 | 1,782,020,224.83 | 1,223,284,970.75 | 686,909,061.52 |
| 二、营业总成本 | 1,941,857,521.47 | 1,468,536,204.53 | 979,179,228.79 | 538,737,974.7 |
| 营业成本 | 1,187,914,554.76 | 917,519,524.02 | 632,770,459.32 | 346,205,232.18 |
| 税金及附加 | 23,293,190.71 | 15,744,301.58 | 11,107,409.56 | 5,757,824.8 |
| 销售费用 | 290,373,566.16 | 211,737,388.26 | 136,298,159.37 | 80,476,077.76 |
| 管理费用 | 181,359,437.04 | 133,850,540.5 | 83,823,829.1 | 41,044,822.78 |
| 研发费用 | 306,171,076.92 | 223,579,922.81 | 143,448,942.59 | 77,257,984.27 |
| 财务费用 | -47,254,304.12 | -33,895,472.64 | -28,269,571.15 | -12,003,967.09 |
| 其中:利息费用 | 3,410,319.59 | 2,470,544.38 | 1,758,321.4 | 842,633.79 |
| 其中:利息收入 | 47,662,107.06 | 37,578,315.51 | 28,268,836.6 | 13,038,215.13 |
| 加:公允价值变动收益 | 5,468,787.54 | -172,721 | -1,139,396.68 | 334,520 |
| 加:投资收益 | 23,794,761.37 | 16,606,073.73 | 11,307,110.66 | 3,291,655.49 |
| 资产处置收益 | 233,571.76 | -124,596.66 | -130,256.06 | -81,512.41 |
| 资产减值损失(新) | -2,756,186.74 | -1,755,038.72 | -1,728,897.13 | -12,496.58 |
| 信用减值损失(新) | -15,535,293.57 | -19,364,586.03 | -15,489,684.14 | -6,728,018.99 |
| 其他收益 | 48,646,778.42 | 32,131,652.64 | 19,865,772.08 | 9,301,428.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 401,827,808.74 | 340,804,804.26 | 256,790,390.69 | 154,276,662.98 |
| 加:营业外收入 | 3,247,061.03 | 2,970,937.9 | 2,095,775.24 | 446,140.86 |
| 减:营业外支出 | 3,118,165.04 | 1,357,245.63 | 17,278.86 | 21,412.15 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 401,956,704.73 | 342,418,496.53 | 258,868,887.07 | 154,701,391.69 |
| 减:所得税费用 | 20,948,658.93 | 23,440,550.64 | 19,731,759.14 | 12,849,152.72 |
| 六、净利润 | 381,008,045.8 | 318,977,945.89 | 239,137,127.93 | 141,852,238.97 |
| 持续经营净利润 | 381,008,045.8 | 318,977,945.89 | 239,137,127.93 | 141,852,238.97 |
| 归属于母公司股东的净利润 | 366,632,797.05 | 309,141,846.32 | 234,342,835.01 | 137,614,697.49 |
| 少数股东损益 | 14,375,248.75 | 9,836,099.57 | 4,794,292.92 | 4,237,541.48 |
| (一)基本每股收益 | 1.16 | 0.98 | 0.74 | 0.44 |
| (二)稀释每股收益 | 1.16 | 0.98 | 0.74 | 0.44 |
| 八、其他综合收益 | -13,065,819.88 | -23,664,262.3 | -24,452,127.42 | 12,754.54 |
| 归属于母公司股东的其他综合收益 | -13,065,819.88 | -23,664,262.3 | -24,452,127.42 | 12,754.54 |
| 九、综合收益总额 | 367,942,225.92 | 295,313,683.59 | 214,685,000.51 | 141,864,993.51 |
| 归属于母公司股东的综合收益总额 | 353,566,977.17 | 285,477,584.02 | 209,890,707.59 | 137,627,452.03 |
| 归属于少数股东的综合收益总额 | 14,375,248.75 | 9,836,099.57 | 4,794,292.92 | 4,237,541.48 |
| 公告日期 | 2025-03-29 | 2024-10-30 | 2024-08-23 | 2024-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |